Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Stock-Based Compensation Awards Granted

The consolidated stock-based compensation expense recognized by each of PAVmed Inc. and Lucid Diagnostics Inc. for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows:

	2021		2020		2021		2020
	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Commercial operations expenses	$	298	$	64	$	500	$	98
General and administrative expenses		4,599		343		5,722		586
Research and development expenses		306		122		417		188
Total stock-based compensation expenses	$	5,203	$	529	$	6,639	$	872

Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses

The stock-based compensation expense recognized by Lucid Diagnostics Inc. for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Lucid Diagnostics Inc 2018 Equity Plan – general and administrative expense	$	2,505	$	—	$	3,295	$	—
Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses		22		13		34		27
PAVmed Inc 2014 Equity Plan - research and development expenses		53		3		56		6
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc	$	2,580	$	16	$	3,385	$	33

Schedule of Unrecognized Compensation Expense

The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows:

	Unrecognized Expense		Weighted Average Remaining  Service Period
PAVmed Inc. 2014 Equity Plan
Stock Options	$	7,595		1.6 years
Restricted Stock Awards	$	2,716		2.2 years
Lucid Diagnostics Inc. 2018 Equity Plan
Stock Options	$	25		0.7 years
Restricted Stock Awards	$	16,826		1.7 years

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions

	Six Months Ended June 30,
	2021			2020
Expected term of stock options (in years)		5.6			5.8
Expected stock price volatility		75	%		73	%
Risk free interest rate		1.0	%		0.5	%
Expected dividend yield		0	%		0	%

2014 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Summarizes Information About Stock Options

Stock options issued and outstanding under the PAVmed Inc. 2014 Equity Plan is as follows:

	Number Stock Options			Weighted Average Exercise Price		Remaining Contractual Term (Years)	Intrinsic Value(2)
Outstanding stock options at December 31, 2020		6,798,529		$	2.55
Granted(1)		2,355,000		$	4.59
Exercised		(120,832	)	$	1.08
Forfeited		(25,833	)	$	2.44
Outstanding stock options - June 30, 2021		9,006,864		$	3.11	6.9	$	29,843
Vested and exercisable stock options - June 30, 2021		5,972,706		$	2.89	5.7	$	21,289

⁽¹⁾ Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.

⁽²⁾ The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of June 30, 2021 and December 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

2018 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Summarizes Information About Stock Options

Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan is as follows:

	Number Stock Options		Weighted Average Exercise Price		Remaining Contractual Term (Years)
Outstanding stock options at December 31, 2020		991,667	$	0.86		8.0
Granted(1)		—	$	—
Exercised		—	$	—
Forfeited		—	$	—
Outstanding stock options at June 30, 2021		991,667	$	0.85		7.5
Vested and exercisable stock options at June 30, 2021		876,666	$	0.83		7.4

⁽¹⁾ Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.